drugset / Trial / NCT01747915

A Safety, Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric and Adult Subjects With Primary Generalized Tonic-Clonic (i.e., Grand Mal) Seizures.

NCT01747915

Phase 3 Completed 219 enrolled Viatris Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The study is designed to evaluate the safety, tolerability and efficacy of two doses of pregabalin as add-on treatment in pediatric and adult subjects with Primary Generalized Tonic-Clonic (PGTC) seizures as compared to placebo. It is hypothesized that both doses of pregabalin will demonstrated superior efficacy when compared to placebo by reducing PGTC seizure frequency and that pregabalin will be safe and well tolerated.

Timeline

Start
2013-04-03
Primary completion
2019-02-20
Completion
2019-02-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Pregabalin Small molecule 5 mg/kg
Subject Pregabalin Small molecule 10 mg/kg